NewsRoom Articles - BioMedWire (BMW)

FridayJan 23, 2026 10:00 am

Meta Analysis Finds That Weight Reduction Reduces Severity of Psoriasis

Psoriasis is a chronic skin condition that afflicts at least 60 million individuals globally. Nearly 80% of these affected people also tend to be either overweight or obese. Excess weight has been a known risk factor for psoriasis development, but until now, no rigorous scientific data existed on how the quality of life of patients and the disease severity are impacted when interventions to reduce weight are instituted for psoriatic patients. Now a meta-analysis and systematic review conducted in the UK has established that patients with psoriasis register notable improvements in their quality of life and the severity of the condition reduces when these patients undertake either lifestyle or pharmacological measures aimed at reducing…

ThursdayJan 22, 2026 10:00 am

New Digital Twin Predicts Outcomes of Brain Cancer Treatments

Researchers at the University of Michigan (U-M) have developed a system that leverages both AI and machine learning to create a digital twin of a patient’s brain cancer in order to predict how that patient will respond to different treatments. This tool promises to take personalized cancer care a step higher. The study, whose findings appeared in the journal Cell Metabolism, focused on gliomas. The team sought to establish how to distinguish between patients that are likely to benefit when their diets exclude certain amino acids (proteins) and those who are unlikely to benefit from such dietary changes. Some gliomas starve when these nutrients aren’t available in the food that a patient consumes, but some gliomas can “scavenge” for…

ThursdayJan 22, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy

LIXTE is developing a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments Its lead compound, LB-100, targets PP2A and is advancing through multiple clinical trials with a favorable safety profile The company is building a differentiated oncology pipeline supported by experienced leadership and scientific expertise LIXTE Biotechnology (NASDAQ: LIXT) is a clinical-stage pharmaceutical company leading efforts in addressing some of the pressing challenges in cancer treatment. Instead of developing standalone cancer drugs, the company is adopting a different strategy aimed at enhancing the overall effectiveness of existing immunotherapy and chemotherapy regimens through a novel biological target. LIXTE’s…

WednesdayJan 21, 2026 10:00 am

Scientists Develop Next-Gen Antibodies That Boost the Body’s Cancer Killing Cells

Scientists at Southampton University have created new antibodies that supercharge the immune system’s ability to identify and kill cancer cells. This approach involved clustering immune receptors in the body so that stronger signals can be sent out to the specialized cells responsible for zeroing in and killing cancer cells. Published in the Nature Communications journal, the study documents how this new approach introduces four-pronged antibody cells instead of the two-pronged ones that naturally exist in our bodies. By converting these antibodies into four-pronged ones, the new cells are better able to bind to more receptors in the body so that a more powerful signal is sent to T cells to…

TuesdayJan 20, 2026 9:00 am

Earth Science Tech Inc. (ETST) Is ‘One to Watch’

Earth Science Tech operates a diversified, revenue-generating holding company model with core exposure to pharmaceutical compounding and telemedicine markets. The company has demonstrated operational execution through asset growth, profitability, and disciplined share reduction initiatives. Regulatory alignment, including SIC 2834 pharmaceutical classification and FINRA Form 211 clearance, enhances transparency and market credibility. A multi-subsidiary structure provides organizational flexibility across pharmaceutical, telemedicine, healthcare, real estate, and consumer operating businesses. The company is led by an executive team with experience across operations, finance, technology, and strategic management, providing continuity and oversight across its operating platforms. Earth Science Tech (OTC: ETST) is a strategic holding…

FridayJan 16, 2026 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Announces Positive Phase 2 Data for Rare Inflammatory Disease

Behçet’s disease is characterized by unpredictable flare-ups and periods of remission, making long-term management particularly challenging. Current treatment strategies for the disease focus on controlling inflammation and suppressing immune activity using corticosteroids, immunosuppressants and biologic agents. Soligenix has released positive top-line results from its phase 2 clinical trial evaluating SGX945 for the treatment of aphthous ulcers associated with Behçet’s. Behçet’s disease is a rare, chronic inflammatory condition that can cause recurrent, painful ulcers, eye inflammation and systemic complications that significantly affect quality of life. Because available treatments are limited and often inconsistent, clinical trial updates in this disease area carry…

FridayJan 16, 2026 10:00 am

Experts are Astounded by the Vaccine Policy Change in the US

The recent vaccine policy changes that the U.S. government announced have astounded experts because the changes reduce recommended vaccines by one third and put the U.S. behinds its peer countries. This change shifts the U.S. from the position of leader on vaccination to a country that lags other developed nations on matters of disease prevention. This policy change marks the latest escalation of the HHS secretary, John F. Kennedy Jr., who has for long been a skeptic of vaccines and is now in a position where he can make policy decisions that affect the entire country. Daniel Jernigan, the National Center for Emerging Zoonotic Infectious Diseases’ former director,…

ThursdayJan 15, 2026 9:00 am

Michigan State University Research Says Suppressing Postoperative Pain Could Delay Healing

The normal practice after someone has undergone a surgical procedure has been to administer anti-inflammatory medications. However, new research conducted at Michigan State University (MSU) suggests that this could be counterproductive and may be the reason why some patients develop chronic pain that lasts for years after their surgery. The study found that allowing inflammation to happen naturally expedited the recovery process after injury or surgery and that pain ceased a lot faster if inflammation wasn’t blocked. Associate Professor Geoffroy Laumet, the senior author of the study, explains that the research team was surprised when they found that blocking inflammation…

WednesdayJan 14, 2026 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Advances Solutions for Hard-to-Diagnose CTCL

CTCL is recognized by clinicians as one of the most difficult cancers to diagnose accurately in its early stages. Delayed diagnosis has meaningful clinical consequences. Within this challenging diagnostic and treatment landscape, Soligenix is advancing a novel therapeutic approach for CTCL through its development of HyBryte(TM). Cutaneous T-cell lymphoma, or CTCL, is a rare form of non-Hodgkin lymphoma that primarily affects the skin, often presenting with symptoms that closely resemble common dermatologic conditions such as eczema or psoriasis, leading to frequent misdiagnosis and delayed treatment. These diagnostic delays can allow the disease to progress silently for years, increasing patient suffering…

TuesdayJan 13, 2026 10:00 am

Penn State to Participate in Researching Potential Treatment for Pediatric Brain Cancer

A new collaboration between Penn State College of Medicine and Targepeutics seeks to advance research into a promising combination therapy that offers hope to families with children diagnosed with DIPG (diffuse intrinsic pontine glioma). This glioma is devastating and currently has limited therapy options. Patients diagnosed with this cancer survive for less than a year on average. A new combo therapy involving an immunotoxin dubbed GB13 and radiotherapy has shown promise in preclinical trials where approaches like chemotherapy or targeted therapy have had dismal results. The collaboration seeks to advance this treatment to clinical studies and eventual approval by the FDA. The planned clinical trial seeks to recruit pediatric participants, a reflection of how…